by According to Precedence Research, during the forecast period of 2022 to 2030, the global contraceptive drugs market is estimated to develop at a compound annual growth rate (CAGR) of 5.85%. The global contraceptive drugs market was valued at USD 15.35 billion in 2021, and it is predicted to exceed USD 25.6 billion by 2030. The study investigates several elements and their consequences on the growth of the contraceptive drugs market.
Download Free Sample Copy with TOC@ https://www.precedenceresearch.com/sample/1753
This report focuses on contraceptive drugs market volume and value at the global level, regional level and company level. From a global perspective, this report represents overall contraceptive drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Middle East & Africa, Latin America, etc.
Report Scope of the Contraceptive Drugs Market
| Report Coverage | Details |
| Market Size by 2030 | USD 25.6 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 5.85% |
| Largest Market | North America |
| Fastest Growing Market | Asia-Pacific |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Product, Distribution Channel, Age Group, Geography |
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
In-Depth Analysis on Competitive Landscape
The report sheds light on leading manufacturers of contraceptive drugs, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in the production of contraceptive drugs has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, which include essentials such as product portfolio, key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting market status and predicting the competition level in the contraceptive drugs market.
Some of the prominent players in the contraceptive drugs market include:
- Church & Dwight Co., Inc.
- Reckitt Benckiser Group Plc
- Veru, Inc.
- Organon Group of Companies
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd.
- The Cooper Companies, Inc.
- Mayer Laboratories, Inc.
- Agile Therapeutics
- TherapeuticsmMD, Inc.
- Bayer Ag
- Afaxys, Inc.
- Mithra Pharmaceuticals
- Abbvie
Ask Here For More Customization Study@ https://www.precedenceresearch.com/customization/1753
Segments Covered in the Report
By Product
- Oral
- Pills
- Intrauterine Devices (IUD)
- Hormonal IUD
- Nonhormonal IUD
- Condoms
- Male Condoms
- Female Condoms
- Vaginal Ring
- Subdermal Implants
- Injectable
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Clinics
- Online Channel
- Public Channel & NGOs
- Others
By Age Group
- 15–24 years
- 25–34 years
- 35–44 years
- Above 44 years
Regional Segmentation
- Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
- Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
- North America [United States, Canada, Mexico]
- South America [Brazil, Argentina, Columbia, Chile, Peru]
- Middle East & Africa [GCC, North Africa, South Africa]
Some of the important ones are:
- What can be the best investment choices for venturing into new product and service lines?
- What value propositions should businesses aim at while making new research and development funding?
- Which regulations will be most helpful for stakeholders to boost their supply chain network?
- Which regions might see the demand maturing in certain segments in near future?
- What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
- Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
- Which government regulations might challenge the status of key regional markets?
- How will the emerging political and economic scenario affect opportunities in key growth areas?
- What are some of the value-grab opportunities in various segments?
- What will be the barrier to entry for new players in the market?
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Contraceptive Drugs Market
5.1. COVID-19 Landscape: Contraceptive Drugs Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Contraceptive Drugs Market, By Product
8.1. Contraceptive Drugs Market, by Product, 2022-2030
8.1.1 Oral
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Lead Acid
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Intrauterine Devices (IUD)
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Condoms
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Vaginal Ring
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Subdermal Implants
8.1.6.1. Market Revenue and Forecast (2017-2030)
8.1.7. Injectable
8.1.7.1. Market Revenue and Forecast (2017-2030)
8.1.8. Others
8.1.8.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Contraceptive Drugs Market, By Distribution Channel
9.1. Contraceptive Drugs Market, by Distribution Channel, 2022-2030
9.1.1. Hospital Pharmacy
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Retail Pharmacy
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Clinics
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Online Channel
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Public Channel & NGOs
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Contraceptive Drugs Market, By Age Group
10.1. Contraceptive Drugs Market, by Age Group, 2022-2030
10.1.1. 15–24 years
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. 25–34 years
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. 35–44 years
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Above 44 years
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Contraceptive Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2017-2030)
11.1.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.4.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.4.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.4.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.4.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.4.3. Market Revenue and Forecast, by Age Group (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Age Group (2017-2030)
Chapter 12. Company Profiles
12.1. Church & Dwight Co., Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Reckitt Benckiser Group Plc
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Veru, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Organon Group of Companies
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Pfizer, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Teva Pharmaceutical Industries Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. The Cooper Companies, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Mayer Laboratories, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Agile Therapeutics
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. TherapeuticsmMD, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Buy This Premium Research Report Click Here@ https://www.precedenceresearch.com/checkout/1753
About Us
Precedence Research is a Canada/India based company and one of the leading providers of strategic market insights. We offer executive-level blueprints of markets and solutions beyond flagship surveys. Our repository covers consultation, syndicated market studies, and customized research reports. Through our services we aim at connecting an organization’s goal with lucrative prospects globally.
From gauging investment feasibility to uncovering hidden growth opportunities, our market studies cover in-depth analysis, which also is interspersed with relevant statistics. Recommendation are often enclosed within our reports with the sole intent of enabling organizations achieve mission-critical success.
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
